GlobeNewswire PharmaOriginal article
Moleculin’s MIRACLE R/R AML Trial Reports Positive Interim Data with 37% Blinded CRc in Venetoclax-Failed Patients
Data ReadoutpositiveMIRACLEVenetoclaxPositive
AI Analysis
Summary
Moleculin's MIRACLE trial reported positive interim data showing 37% blinded composite remission rate in relapsed/refractory AML patients who previously failed venetoclax treatment, significantly exceeding historical salvage remission rates of ~13% in this patient population.
Clinical Trial Data
Phase
2
Primary Endpoint
Met
Outcome Details
37% blinded composite remission rate in venetoclax-failed patients, comparing favorably to historical salvage remission rate of approximately 13%
Importance:7/10
Sentiment:
0.75
Phase 2AMLinterim datavenetoclax-resistantrelapsed/refractory
Read the original article
Published by GlobeNewswire Pharma on July 31, 2026 12:10 PM